Venus Medtech (Hangzhou) Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Venus Medtech (Hangzhou) heeft een totaal eigen vermogen van CN¥3.3B en een totale schuld van CN¥778.7M, wat de schuld-eigenvermogensverhouding op 23.4% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥5.0B en CN¥1.7B.

Belangrijke informatie

23.4%

Verhouding schuld/eigen vermogen

CN¥778.68m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥1.45b
Aandelen	CN¥3.32b
Totaal verplichtingen	CN¥1.68b
Totaal activa	CN¥5.00b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥2.1B ) 2500 } overtreffen de korte termijn passiva ( CN¥633.3M ).

Langlopende schulden: De kortetermijnactiva 2500 ( CN¥2.1B ) overtreffen de langetermijnschulden ( CN¥1.0B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 2500 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 2500 is de afgelopen 5 jaar gestegen van 20% naar 23.4%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 2500 heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of 2500 voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Venus Medtech (Hangzhou) Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

No longer forecast to breakeven

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

First half 2022 earnings released: CN¥0.46 loss per share (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Full year 2021 earnings released: CN¥0.85 loss per share (vs CN¥0.45 loss in FY 2020)

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

No longer forecast to breakeven

Forecast breakeven date pushed back to 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven